Robert Kulik

Director, Government Affairs

Teva Innovation

Robert Kulik is the Director of Government Affairs at Teva Canada Limited. Teva Canada specializes in the development, production, and marketing of high-quality generic prescription pharmaceuticals and, through our branded division, focuses on a diverse line of innovative products in a variety of therapeutic areas.

Robert has worked in the biopharmaceutical industry for the past 23 years with a focus on ensuring that Canadian patients have access to innovative medical technologies. He has an expertise in developing and implementing successful, government relations and patient access strategies in several areas, including orphan/rare disease medications, biologics and treatments in specialized and highly targeted populations.  He has also gained valuable experience in assisting companies in establishing successful commercial operations in Canada.

Robert holds a Bachelor of Arts degree in Political Science from York University and Master of Arts in Political Studies from the University of Guelph.  During his studies at Guelph, his research was focused on provincial reimbursement policy in Canada.

Robert and his wife Natalie have two teenage children and live in Oakville Ontario.


All Sessions by Robert Kulik

Printer Friendly See Full Agenda

Day 1: Oct 6, 2020

2:10 pm

2:10 pm

Panel Discussion

Gain Insights into the Impact of the Increasing Use of Biosimilars for Patients and the Marketplace

Many consider that increasing the use of biosimilars is key to putting healthcare budgets on a more financially sustainable path.  Understand the implications and opportunities for your business of recent policy decisions to foster a greater market share for biosimilars.  Develop an action plan to:

  • Prepare and support patients in the event they need to switch to a biosimilar
  • Analyse the impact on your biosimilar strategy of international collaboration to increase biosimilar market share
  • Adapt your Canadian market access strategies with medical and public policy guidance

Inform your strategy for biosimilars with key public policy insights

Day 2: Oct 7, 2020

Day 3: Oct 8, 2020